Daxx Antibody (DAXX-01) [FITC]
Novus Biologicals, part of Bio-Techne | Catalog # NB500-491F
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
Immunocytochemistry/ Immunofluorescence, Western Blot
Label
FITC (Excitation = 495 nm, Emission = 519 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # DAXX-01
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for Daxx Antibody (DAXX-01) [FITC]
Immunogen
Recombinant C-terminal part (aa 558-740) of human Daxx.
Specificity
The antibody DAXX-01 reacts with Daxx, a death domain containing protein mainly expressed in fetal and adult human and mouse tissue.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for Daxx Antibody (DAXX-01) [FITC]
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Daxx
Long Name
Fas Death Domain-associated Protein
Alternate Names
BING2, DAP6
Gene Symbol
DAXX
Additional Daxx Products
Product Documents for Daxx Antibody (DAXX-01) [FITC]
Product Specific Notices for Daxx Antibody (DAXX-01) [FITC]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...